273results about "DsRNA viruses" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention discloses a self-replicating RNA (Ribonucleic Acid) molecule, a porcine rotavirus RNA vaccine and application thereof, and relates to the technical field of vaccines. According to the present invention, the coding sequence of the porcine rotavirus G9P23 type VP4 protein is optimized, such that the fact that the saRNA prepared by using the nucleotide sequence represented by the SEQ ID NO: 10 can secrete the high porcine rotavirus G9P23 type VP4 protein antigen after the cell transfection is found; after the optimized porcine rotavirus G9P23 type VP4 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the challenge protection effect is enhanced. Therefore, the nucleic acid molecule provided by the invention can be used for developing drugs and vaccines for causing protective immune response in experimental animal bodies. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

Disclosed herein, in certain embodiments, are non-enveloped capsid delivery systems which comprise a viral capsid polypeptide and a heterologous cargo, as well as methods of making and using such non-enveloped capsid delivery systems.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

The invention discloses a porcine rotavirus VP7 protein conservative dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application thereof, and further discloses a porcine rotavirus VP7 protein multi-epitope fusion protein and a preparation method and application thereof. The multi-epitope fusion protein disclosed by the invention not only can induce high-level specific antibody response and cellular immune response aiming at the VP7 protein and effectively inhibit porcine rotavirus infection, but also has relatively high safety and stability. Compared with the traditional fusion protein, the multi-epitope fusion protein disclosed by the invention has remarkable advantages in the aspects of production cost, immune efficacy and the like, and a feasible porcine rotavirus prevention and control scheme is provided for the pig industry.

The invention relates to a Vero cell serum-free culture medium and application thereof, the serum-free culture medium is suitable for free suspension growth of Vero cells and is free of animal sources and protein components, adherent cells can be directly domesticated through a certain method to screen out Vero suspension cells, and serum-free suspension culture of the Vero suspension cells is achieved in the serum-free culture medium. The density of cells subjected to suspension culture by adopting the serum-free culture medium can reach more than 107 cells / mL, the cell viability is more than 90%, the cells are well dispersed, the cells can still normally grow and proliferate after continuous subculture for 20 generations, and the cells are sensitive to various viruses.

The invention relates to a novel fish virus, indicated to be a Totivirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.

The invention provides a porcine rotavirus type G9 (PoRV) and an application of the porcine rotavirus type G9 (PoRV). According to the present invention, the porcine rotavirus G9 type SC01 strain is separated from the porcine intestinal tract tissue, and is subjected to passage purification to obtain the porcine rotavirus G9 type SC01 strain, and the microbial preservation number of the porcine rotavirus G9 type SC01 strain is CGMCC No.46200; the isolated strain can stably proliferate on passage cells to generate typical cytopathy. The porcine rotavirus G9 type isolate has excellent immunogenicity, and a vaccine prepared from the isolate can induce piglets to generate high-level neutralizing antibodies; the ELISA kit prepared by adopting the isolated strain can be used for well detecting the porcine rotavirus G9 type antibody in serum.

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

Disclosed are polynucleotides, and collections of polynucleotides, encoding segments of novel recombinant OSU strain rotaviruses and methods of making the same, systems for generating the same, as well as methods of using the same to elicit an immune response in a subject or to vaccinate a subject against rotavirus infection and infection.

The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.

The invention relates to a novel fish virus, indicated to be a Totivirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

A poultry vaccine against infectious bronchitis and turkey rhinotracheitis is provided. The vaccine is adjuvanted with an oil emulsion containing immunostimulatory oligonucleotides. Methods of using the vaccine are also provided. [Selection diagram] None

The invention relates to a porcine bacterial polysaccharide-viral protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of animal vaccines. The vaccine takes porcine bacterial polysaccharide and virus protein as raw materials, and a polysaccharide-virus protein conjugate is formed through coupling of a biotin-avidin system; wherein the virus protein is selected from one of classical swine fever virus E2 protein, porcine circovirus type 2 Cap protein, porcine pseudorabies virus gD protein and the like, and the porcine bacterial polysaccharide is selected from one of streptococcus suis capsular polysaccharide, porcine pasteurella multocida capsular polysaccharide and the like. The vaccine can simultaneously induce an organism to generate a high-level IgG antibody aiming at porcine bacterium capsular polysaccharide and virus protein, so that synergistic immune protection on porcine bacterium and virus infection is realized, and a broad-spectrum cross immune effect is achieved.

The present application provides a truncated protein of porcine rotavirus VP4 and its expression and application in preventing and treating porcine diarrhea; the amino acid sequence of the truncated protein of porcine rotavirus VP4 of the present application is SEQ ID NO.3, which has improved immunogenicity by appropriately truncating the nitrogen-terminal part of VP4 and introducing histidine and proline mutations; and can be used to prepare injectable / oral vaccines or drugs.

The invention discloses a vaccine freeze-dried heat-resistant protective agent and a preparation method and application thereof. The freeze-dried heat-resistant protective agent consists of the following components in weight percentage: 0.6-1.0% of gelatin, 4.5-6.5% of brain heart infusion, 3.5-5.5% of tryptone, 6-10% of trehalose, 2.0-3.0% of sucrose, 1.5-2.5% of sodium thiosulfate, 0.6-1.2% of polyvinyl pyrrolidone (PVPK30), 0.4-0.6% of dextran, 0.3-0.5% of mannitol, 0.2-0.4% of glycine, 0.04-0.06% of sodium glutamate, 0.2-0.3% of L-arginine, and the balance is water for injection. The freeze-dried heat-resistant protective agent of the vaccine disclosed by the invention has components that interact with each other, thereby improving the temperature tolerance of porcine infectious gastroenteritis, porcine epidemic diarrhea and porcine rotavirus triple live vaccines during freeze-drying, reducing the loss of efficacy, and the virus loss rate before and after freeze-drying does not exceed 0.2 titers.

The invention relates to the technical field of rotaviruses, in particular to a G8P [8] type group A rotavirus CZ-23 and application thereof. The invention relates to a G8P [8] type group A rotavirus CZ-23, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 11, 2023, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides a novel human rotavirus wild strain which is reported and separated for the first time in China, and the strain is strong in virus replication capability and good in hereditary stability, can be applied to development of vaccine strains of human rotavirus vaccines, and is suitable for attenuated rotavirus oral vaccines.

The invention belongs to the technical field of virus detection, and particularly relates to an anguilla positive reovirus (Anguilla positive reovirus) AORV-1025 as well as a primer group, a kit and a method for detecting the anguilla positive reovirus. According to the invention, a conserved sequence of an RdRp gene coded by an L3 segment of an eel positive reovirus genome is taken as a target, a primer group consisting of a primer pair and a probe is designed, and the primer group is used for detecting several different positive reoviruses including the eel positive reovirus and viruses possibly existing in a detection sample. The detection result is high in sensitivity, strong in specificity and excellent in repeatability, the eel positive reovirus in a sample can be rapidly and accurately detected in a fluorescent quantitative mode, the method is applied to research on eel positive reovirus infection, and the method has important significance on pathogen monitoring, differential diagnosis and guide prevention and control of eel viral diseases.

The present invention relates to a combination vaccine comprising the antigens: a) Cryptosporidium parvum gp40; b) inactivated bovine rotavirus; c) inactivated bovine coronavirus; and d) E. coli fimbrial adhesins F5 and F41. In addition, the invention relates to methods for the preparation of the vaccine, methods for vaccinating ruminants against infection by Cryptosporidium parvum, bovine rotavirus, bovine coronavirus and E. coli, and to a kit-of-parts at least comprising a container comprising the at least one antigen according to the invention.

The present invention relates to recombinant Marek's disease viruses containing, inserted into at least one insertion site, at least one recombinant nucleotide sequence encoding an antigen operably linked to a promoter and an insulator, their manufacture, compositions comprising the same, and the uses thereof.

The invention relates to a cherry valley duck PLV virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus immunity. The vaccine is prepared by taking a Parry's Lagon virus (PLV) virus strain PLV-20155 as an immunogen, the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46296. The invention further discloses a preparation method of the vaccine. The vaccine is a PLV-20155 virus inactivated vaccine, and the preparation method of the vaccine comprises the following steps: inoculating the PLV-20155 virus into an SPF chick embryo for propagation, harvesting a virus liquid, inactivating with formaldehyde, verifying safety, emulsifying with white oil to prepare the vaccine and the like. In addition, the vaccine disclosed by the invention can be used for effectively preventing diseases such as laying rate reduction, follicle necrosis and fallopian tube atrophy of the cherry valley ducks caused by the PLV-20155 virus, and the economic benefit of breeding is remarkably improved.

Attenuated isolates of avian reoviruses associated viral arthritis / tenosynovitis in poultry are presented, including avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077 and progeny or derivatives thereof and avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or compositions as vaccines to control of reovims-induced viral arthritis / tenosynovitis in birds of the order Galliformes are also presented.

The present invention describes immunogenic compositions containing immunogenic polypeptides of Porcine circovirus 2e, 3c, or 4 (PCV2e, PCV3c, or PCV4), including immunogenic compositions containing antigens other than PCV2e, PCV3c, or PCV4 antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating a PCV2e, PCV3c, or PCV4 infection are also described.

The invention discloses a pelteobagrus fulvidraco brain tissue cell line PYCB sensitive to viruses and application thereof, and belongs to the technical field of aquatic organism cell culture and disease prevention and control. The preservation number of the Pelteobagrus fulvidraco brain tissue cell line PYCB is CCTCC (China Center For Type Culture Collection) NO: C2025148. The Pelteobagrus fulvidraco brain tissue cell line PYCB is successfully constructed by taking the Pelteobagrus fulvidraco brain tissue as an object, and the cell line can be continuously and stably subcultured, is high in proliferation speed and simple in culture method, is sensitive to Pelteobagrus fulvidraco small RNA viruses and Pelteobagrus fulvidraco stem casing viruses, and can be used for isolated culture of viruses. The invention provides an important research platform and an experimental material for separating and identifying fish viruses and virus vaccines and developing medicines.

A modified adenoviral vector, lacking splice acceptor dinucleotides in a region of the vector and having improved expression is provided.